- ￥1710 - 7110
- 爱必信(absin)
- abs823379
- 上海
- 2025年07月09日
企业认证
相关产品推荐更多 >
![[(1S,3S)-3-[[4-Methoxy-3-(3-methoxypropoxy)phenyl]methyl]-4-methyl-1-[(2S)-tetrahydro-4-(1-methylethyl)-5-oxo-2-furanyl]](https://img1.dxycdn.com/2022/1124/352/2842169574477474853-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
现货
- 英文名：
(S)-p38 Mitogen-activated Protein Kinase Inhibitor III
- CAS号：
581098-48-8
- 保质期：
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
- 供应商：
爱必信(上海)生物科技有限公司
- 保存条件：
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
- 规格：
1mg/5mg
| 规格： | 1mg | 产品价格： | ￥1710.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥7110.0 |
| 产品描述 | |
| 描述 | (S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 µM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 µM, respectively). |
| 应用 | A cell-permeable potent, selective, and ATP competitive p38 MAP kinase inhibitor |
| 纯度 | ≥98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 形态 | Solid |
| 基本信息 | |
| 别名 | (S)-p38 Mitogen-activated Protein Kinase Inhibitor III |
| IC50 | p38α MAP kinase: IC50 = 0.38 µM; TNF-α release: IC50 = 0.16 µM (human PBMC); IL-1β release: IC50 = 0.039 µM (human PBMC) |
| 可溶性/溶解性 | Soluble in DMSO. |
| PubChem CID | 6419739 |
分子结构图：
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关专题 MAPK信号通路专题 G-protein-coupled receptors (GPCR s) are activated by a wide variety of external stimuli. Upon receptor activation the G-protein exchanges GDP for GTP, causing the dissociation of the GTP-bound
and Raf intermediates prior to phosphorylating three or more MAPKs in sequence. The MAPK pathway’s ubiquitous nature ensures that this pathway mediates the vast majority of cellular responses. Aberrant MAPK activity, including constitutive activation
intermediates prior to phosphorylating three or more MAPKs in sequence. The MAPK pathway’s ubiquitous Nature ensures that this pathway mediates the vast majority of cellular responses. Aberrant MAPK activity, including constitutive activation
技术资料暂无技术资料 索取技术资料
